Published in Muscle Nerve on May 01, 2006
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Transthyretin (TTR) cardiac amyloidosis. Circulation (2012) 1.40
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res (2014) 1.18
Amyloid neuropathies. Mt Sinai J Med (2012) 1.08
Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener (2014) 1.07
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc (2012) 1.03
Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov (2015) 1.02
Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther (2011) 0.99
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One (2012) 0.96
Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol (2013) 0.93
Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89
Endogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils through Different Receptors. Front Immunol (2013) 0.86
Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis. Appl Clin Genet (2012) 0.85
Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol (2010) 0.84
Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord (2013) 0.84
Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83
Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett (2009) 0.82
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol (2012) 0.80
Evolving landscape in the management of transthyretin amyloidosis. Ann Med (2015) 0.80
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol (2016) 0.77
Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells. PLoS One (2016) 0.75
Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis. Eur J Nucl Med Mol Imaging (2011) 0.75
Accelerating restrictive cardiomyopathy after liver transplantation in a patient with familial amyloidotic polyneuropathy: a case report. J Med Case Rep (2008) 0.75
The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy. PLoS One (2015) 0.75
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
A 71-year-old woman with multiple myeloma status after stem cell transplantation. Clin Chem (2011) 2.25
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest (2004) 1.93
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int (2008) 1.47
Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem (2004) 1.32
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology (2006) 1.29
NsrR targets in the Escherichia coli genome: new insights into DNA sequence requirements for binding and a role for NsrR in the regulation of motility. Mol Microbiol (2009) 1.27
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood (2008) 1.21
Regulation of the follicle-stimulating hormone beta gene by the LHX3 LIM-homeodomain transcription factor. Endocrinology (2004) 1.20
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem (2004) 1.17
Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes (2010) 1.14
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol (2011) 1.11
Clinical implication of centrosome amplification in plasma cell neoplasm. Blood (2005) 1.11
Acute-phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res (2008) 1.11
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve (2009) 1.09
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. Mol Pharmacol (2013) 1.02
Outcomes of patients with POEMS syndrome treated initially with radiation. Blood (2013) 1.02
Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol (2010) 1.01
Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 1.01
Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol (2012) 1.01
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 0.99
Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol Pharmacol (2012) 0.98
Aging in heterozygous Dnmt1-deficient mice: effects on survival, the DNA methylation genes, and the development of amyloidosis. J Gerontol A Biol Sci Med Sci (2006) 0.97
Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem (2007) 0.95
Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk (2010) 0.95
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc (2010) 0.95
Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol Pharmacol (2012) 0.93
Escherichia coli NsrR regulates a pathway for the oxidation of 3-nitrotyramine to 4-hydroxy-3-nitrophenylacetate. J Bacteriol (2008) 0.91
Isolated amyloidosis presenting with lumbosacral radiculoplexopathy: description of two cases and pathogenic review. J Peripher Nerv Syst (2006) 0.90
The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci (2011) 0.89
Model of pediatric pituitary hormone deficiency separates the endocrine and neural functions of the LHX3 transcription factor in vivo. Proc Natl Acad Sci U S A (2010) 0.88
Induction of heme oxygenase-1 and ferritin in the kidney in warm antibody hemolytic anemia. Am J Kidney Dis (2008) 0.88
Some unusual complications of malignancies: case 2. Marantic endocarditis in advanced cancer. J Clin Oncol (2002) 0.88
The Diflunisal Trial: study accrual and drug tolerance. Amyloid (2012) 0.87
An on-line assay for clinical detection of amyloidogenic transthyretin variants directly from serum. Amyloid (2003) 0.87
Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid (2015) 0.86
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood (2012) 0.86
Transgenic mice expressing LHX3 transcription factor isoforms in the pituitary: effects on the gonadotrope axis and sex-specific reproductive disease. J Cell Physiol (2007) 0.86
Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep (2009) 0.85
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol (2010) 0.85
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica (2013) 0.85
Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl (2003) 0.84
Genetic defects in the development and function of the anterior pituitary gland. Ann Med (2002) 0.83
Hodgkin's lymphoma manifesting with hypoglycemia. Endocr Pract (2003) 0.83
A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis. Amyloid (2003) 0.83
An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid (2003) 0.82
Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease. J Biol Chem (2007) 0.81
Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid (2010) 0.81
Acute-phase response protein serum amyloid A stimulates renal tubule formation: studies in vitro and in vivo. Am J Physiol Renal Physiol (2009) 0.81
Cellular events associated with the initial phase of AA amyloidogenesis: insights from a human monocyte model. Amyloid (2007) 0.81
Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma. Muscle Nerve (2012) 0.80
Intravenous cell therapy for acute renal failure with serum amyloid A protein-reprogrammed cells. Am J Physiol Renal Physiol (2010) 0.80
Renal transplantation for apolipoprotein AII amyloidosis. Amyloid (2003) 0.78
Human SAA1-derived amyloid deposition in cell culture: a consistent model utilizing human peripheral blood mononuclear cells and serum-free medium. Amyloid (2013) 0.78
Immunoglobulin D amyloidosis: a distinct entity. Blood (2011) 0.78
Amyloid-enhancing factor mediates amyloid formation on fibroblasts via a nidus/template mechanism. Arthritis Rheum (2003) 0.78
Two causes of demyelinating neuropathy in one patient: CMT1A and POEMS syndrome. Can J Neurol Sci (2007) 0.77
Conserved amino acid sequences confer nuclear localization upon the Prophet of Pit-1 pituitary transcription factor protein. Gene (2004) 0.77
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol (2015) 0.76
Genotype, echocardiography, and survival in familial transthyretin amyloidosis. Amyloid (2013) 0.76
Getting to the heart of the matter: cardiac involvement in transthyretin-related amyloidosis. Eur Heart J (2012) 0.75
Correction: A Novel Humanized GLP-1 Receptor Model Enables Both Affinity Purification and Cre-LoxP Deletion of the Receptor. PLoS One (2015) 0.75